Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

Citation
Hs. Friedman et al., Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice, CANC CHEMOT, 48(5), 2001, pp. 413-416
Citations number
21
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
0344-5704 → ACNP
Volume
48
Issue
5
Year of publication
2001
Pages
413 - 416
Database
ISI
SICI code
0344-5704(200111)48:5<413:AOI(IT>2.0.ZU;2-R
Abstract
Purpose: This study was conducted to define the activity of irofulven in th e treatment of a series of xenografts derived from human glioblastoma multi forme growing subcutaneously and intracranially in athymic nude mice. Metho ds: Athymic mice bearing subcutaneous or intracranial tumors were treated w ith irofulven at a 10% lethal dose with responses compared to tumor-bearing mice treated with drug vehicle. Results: Irofulven was active against all tumor lines tested with growth delays ranging from 5.6 to 81.6 days (all va lues statistically significant, P less than or equal to 0.001). Irofulven a lso produced a statistically significant (P less than or equal to 0.001) in crease in the median survival Of mice bearing D-456 intracranial xenografts with a 162% increase in median survival. Conclusions: Irofulven is active in a spectrum of human glioblastoma multiforme-derived xenografts and evalu ation in patients with this neoplasm is warranted.